Nektar Therapeutics has announced new data from the ongoing Phase 2b REZOLVE-AD clinical study evaluating rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell biologic, in patients with moderate-to-severe atopic dermatitis. The results were presented on November 8, 2025, in a late-breaking oral abstract session at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. The study demonstrated statistically significant and clinically meaningful improvements in key efficacy endpoints, including mean ACQ-5 scores at week 16 versus placebo in patients with atopic dermatitis and a history of asthma. Additional improvements were observed across major endpoints such as EASI-75, EASI-90, vIGA-AD, and NRS-Itch at Week 16, with continued benefits noted from Week 16 to 24. Data from the long-term maintenance portion of the study, with 52 weeks of treatment, are expected in the first quarter of 2026. Nektar also indicated that top-line Phase 2b data for rezpegaldesleukin in alopecia areata will be reported in December 2025.